{"id":41078,"date":"2025-09-10T15:46:27","date_gmt":"2025-09-10T07:46:27","guid":{"rendered":"https:\/\/flcube.com\/?p=41078"},"modified":"2025-09-10T15:46:28","modified_gmt":"2025-09-10T07:46:28","slug":"kexing-biopharm-secures-global-rights-to-humanwell-puracaps-nintedanib","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=41078","title":{"rendered":"Kexing\u202fBiopharm Secures Global Rights to Humanwell PuraCap\u2019s Nintedanib"},"content":{"rendered":"\n<p>China\u2011listed <strong>Kexing Biopharm Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/688136:SHA\">SHA: 688136<\/a>)<\/strong> announced today a strategic commercialization agreement with <strong>Humanwell PuraCap Pharmaceutical (Wuhan) Co., Ltd.<\/strong>, a subsidiary of <strong>Humanwell Healthcare Group Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/600079:SHA\">SHA: 600079<\/a>)<\/strong>. The deal grants Kexing the rights to market <strong>nintedanib ethanesulfonate<\/strong> soft capsules worldwide\u2014excluding China (mainland, Hong Kong, Macau, Taiwan), the United States, Saudi Arabia, Ecuador, Bolivia, Paraguay, and Uruguay.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-what-the-agreement-covers\">What the Agreement Covers<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Region<\/th><th>Status<\/th><\/tr><\/thead><tbody><tr><td><strong>All other global markets<\/strong><\/td><td>Kexing holds exclusive commercial rights<\/td><\/tr><tr><td><strong>China (incl. HK, Macau, TW)<\/strong><\/td><td>Humanwell PuraCap retains sales<\/td><\/tr><tr><td><strong>United States, Saudi Arabia, Ecuador, Bolivia, Paraguay, Uruguay<\/strong><\/td><td>Excluded from Kexing\u2019s portfolio<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-why-nintedanib-matters\">Why Nintedanib Matters<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong> \u2013 Multi\u2011target tyrosine\u2011kinase inhibitor that blocks VEGFR, PDGFR, and FGFR, curbing fibroblast proliferation and inflammatory pathways.<\/li>\n\n\n\n<li><strong>Clinical Use<\/strong> \u2013 First\u2011line therapy for idiopathic pulmonary fibrosis (IPF).<\/li>\n\n\n\n<li><strong>History<\/strong> \u2013 Originally launched by Boehringer Ingelheim under the brand <strong>Ofev<\/strong> (2017); Humanwell PuraCap\u2019s generic received Chinese approval in September\u202f2023.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>For Kexing<\/strong> \u2013 Expands its oncology\u2011dermal portfolio into a high\u2011growth respiratory indication with proven global demand.<\/li>\n\n\n\n<li><strong>For Humanwell PuraCap<\/strong> \u2013 Secures a dedicated partner to drive commercialization outside its core markets while retaining China\u2011centric sales.<\/li>\n\n\n\n<li><strong>For Investors<\/strong> \u2013 The partnership leverages Kexing\u2019s robust commercial network and Humanwell\u2019s manufacturing excellence, positioning both companies for accelerated revenue growth in an increasingly competitive IPF landscape.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>China\u2011listed Kexing Biopharm Co., Ltd. (SHA: 688136) announced today a strategic commercialization agreement with Humanwell&#8230;<\/p>\n","protected":false},"author":1,"featured_media":41080,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,11],"tags":[31,266,3625,1098,1229],"class_list":["post-41078","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","category-drug","tag-generic-drugs","tag-humanwell-healthcare","tag-kexing-biopharm","tag-sha-600079","tag-sha-688136"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Kexing\u202fBiopharm Secures Global Rights to Humanwell PuraCap\u2019s Nintedanib - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2011listed Kexing Biopharm Co., Ltd. (SHA: 688136) announced today a strategic commercialization agreement with Humanwell PuraCap Pharmaceutical (Wuhan) Co., Ltd., a subsidiary of Humanwell Healthcare Group Co., Ltd. (SHA: 600079). The deal grants Kexing the rights to market nintedanib ethanesulfonate soft capsules worldwide\u2014excluding China (mainland, Hong Kong, Macau, Taiwan), the United States, Saudi Arabia, Ecuador, Bolivia, Paraguay, and Uruguay.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=41078\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kexing\u202fBiopharm Secures Global Rights to Humanwell PuraCap\u2019s Nintedanib\" \/>\n<meta property=\"og:description\" content=\"China\u2011listed Kexing Biopharm Co., Ltd. (SHA: 688136) announced today a strategic commercialization agreement with Humanwell PuraCap Pharmaceutical (Wuhan) Co., Ltd., a subsidiary of Humanwell Healthcare Group Co., Ltd. (SHA: 600079). The deal grants Kexing the rights to market nintedanib ethanesulfonate soft capsules worldwide\u2014excluding China (mainland, Hong Kong, Macau, Taiwan), the United States, Saudi Arabia, Ecuador, Bolivia, Paraguay, and Uruguay.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=41078\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-10T07:46:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-10T07:46:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1005.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41078#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41078\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Kexing\u202fBiopharm Secures Global Rights to Humanwell PuraCap\u2019s Nintedanib\",\"datePublished\":\"2025-09-10T07:46:27+00:00\",\"dateModified\":\"2025-09-10T07:46:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41078\"},\"wordCount\":226,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41078#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1005.webp\",\"keywords\":[\"Generic drugs\",\"Humanwell Healthcare\",\"Kexing Biopharm\",\"SHA: 600079\",\"SHA: 688136\"],\"articleSection\":[\"Company\",\"Deals\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41078#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41078\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=41078\",\"name\":\"Kexing\u202fBiopharm Secures Global Rights to Humanwell PuraCap\u2019s Nintedanib - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41078#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41078#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1005.webp\",\"datePublished\":\"2025-09-10T07:46:27+00:00\",\"dateModified\":\"2025-09-10T07:46:28+00:00\",\"description\":\"China\u2011listed Kexing Biopharm Co., Ltd. (SHA: 688136) announced today a strategic commercialization agreement with Humanwell PuraCap Pharmaceutical (Wuhan) Co., Ltd., a subsidiary of Humanwell Healthcare Group Co., Ltd. (SHA: 600079). The deal grants Kexing the rights to market nintedanib ethanesulfonate soft capsules worldwide\u2014excluding China (mainland, Hong Kong, Macau, Taiwan), the United States, Saudi Arabia, Ecuador, Bolivia, Paraguay, and Uruguay.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41078#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41078\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41078#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1005.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1005.webp\",\"width\":1080,\"height\":608,\"caption\":\"Kexing\u202fBiopharm Secures Global Rights to Humanwell PuraCap\u2019s Nintedanib\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41078#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kexing\u202fBiopharm Secures Global Rights to Humanwell PuraCap\u2019s Nintedanib\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Kexing\u202fBiopharm Secures Global Rights to Humanwell PuraCap\u2019s Nintedanib - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2011listed Kexing Biopharm Co., Ltd. (SHA: 688136) announced today a strategic commercialization agreement with Humanwell PuraCap Pharmaceutical (Wuhan) Co., Ltd., a subsidiary of Humanwell Healthcare Group Co., Ltd. (SHA: 600079). The deal grants Kexing the rights to market nintedanib ethanesulfonate soft capsules worldwide\u2014excluding China (mainland, Hong Kong, Macau, Taiwan), the United States, Saudi Arabia, Ecuador, Bolivia, Paraguay, and Uruguay.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=41078","og_locale":"en_US","og_type":"article","og_title":"Kexing\u202fBiopharm Secures Global Rights to Humanwell PuraCap\u2019s Nintedanib","og_description":"China\u2011listed Kexing Biopharm Co., Ltd. (SHA: 688136) announced today a strategic commercialization agreement with Humanwell PuraCap Pharmaceutical (Wuhan) Co., Ltd., a subsidiary of Humanwell Healthcare Group Co., Ltd. (SHA: 600079). The deal grants Kexing the rights to market nintedanib ethanesulfonate soft capsules worldwide\u2014excluding China (mainland, Hong Kong, Macau, Taiwan), the United States, Saudi Arabia, Ecuador, Bolivia, Paraguay, and Uruguay.","og_url":"https:\/\/flcube.com\/?p=41078","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-10T07:46:27+00:00","article_modified_time":"2025-09-10T07:46:28+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1005.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=41078#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=41078"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Kexing\u202fBiopharm Secures Global Rights to Humanwell PuraCap\u2019s Nintedanib","datePublished":"2025-09-10T07:46:27+00:00","dateModified":"2025-09-10T07:46:28+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=41078"},"wordCount":226,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=41078#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1005.webp","keywords":["Generic drugs","Humanwell Healthcare","Kexing Biopharm","SHA: 600079","SHA: 688136"],"articleSection":["Company","Deals","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=41078#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=41078","url":"https:\/\/flcube.com\/?p=41078","name":"Kexing\u202fBiopharm Secures Global Rights to Humanwell PuraCap\u2019s Nintedanib - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=41078#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=41078#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1005.webp","datePublished":"2025-09-10T07:46:27+00:00","dateModified":"2025-09-10T07:46:28+00:00","description":"China\u2011listed Kexing Biopharm Co., Ltd. (SHA: 688136) announced today a strategic commercialization agreement with Humanwell PuraCap Pharmaceutical (Wuhan) Co., Ltd., a subsidiary of Humanwell Healthcare Group Co., Ltd. (SHA: 600079). The deal grants Kexing the rights to market nintedanib ethanesulfonate soft capsules worldwide\u2014excluding China (mainland, Hong Kong, Macau, Taiwan), the United States, Saudi Arabia, Ecuador, Bolivia, Paraguay, and Uruguay.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=41078#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=41078"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=41078#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1005.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1005.webp","width":1080,"height":608,"caption":"Kexing\u202fBiopharm Secures Global Rights to Humanwell PuraCap\u2019s Nintedanib"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=41078#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Kexing\u202fBiopharm Secures Global Rights to Humanwell PuraCap\u2019s Nintedanib"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1005.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41078","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=41078"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41078\/revisions"}],"predecessor-version":[{"id":41081,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41078\/revisions\/41081"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/41080"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=41078"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=41078"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=41078"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}